
    
      Primary Objective for Phase I

        1. To determine the maximally tolerated dose (MTD) of daily Oral dasatinib in combination
           with cetuximab/RT in Cohort A, in patients with AJCC stage II (T2N0) and III (T1-2N1)
           SCCHN of oral cavity, oropharynx, T2N0 hypopharynx, T2N0-1 supraglottic larynx.

        2. To determine the MTD of daily oral dasatinib in combination with cisplatin/cetuximab/RT
           in Cohort B, in patients with AJCC stage III (T3N0-1) and IV (T1-4N2-3M0, T4N0-1M0)
           squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, and larynx.
    
  